Melt Pharmaceuticals Improves Patent Estate for Sublingual Non-Opioid Pain and Sedation Formulations
13 Februar 2019 - 1:00PM
Melt Pharmaceuticals, Inc., a specialty pharmaceutical company
recently deconsolidated from Harrow Health, Inc. (NASDAQ: HROW),
today announced the U.S. Patent and Trademark office has issued two
additional patents covering the company’s innovative sublingual,
non-opioid pain and sedation formulations. U.S. Patents
10,166,240 and 10,179,136 relate to methods of use, formulation
compositions and methods to manufacture the same, which the company
intends to commercialize through its MELT-100 program and other
planned drug development initiatives. Both new patents have
expiration dates in 2036.
About Melt Pharmaceuticals
Melt Pharmaceuticals, Inc., is a development
stage specialty pharmaceutical company focused on the development
and commercialization of patented non-opioid and non-intravenous
(or non-IV) sedation and anesthesia therapeutics for human medical
procedures in hospital, outpatient, and in-office settings.
Melt intends to seek regulatory approval through the U.S. Food and
Drug Administration’s 505(b)(2) regulatory pathway for these
proprietary technologies. Melt’s core technology is a series
of combination non-opioid sedation drug formulations that may
replace or supplement current sedation modalities for more than 100
million medical procedures in the United States.
Melt Pharmaceuticals’ vision is to be the
leading provider of non-opioid, non-intravenous conscious sedation
and analgesia pharmaceuticals used for human medical procedures in
hospital, outpatient, and in-office settings.
ABOUT MELT-100
MELT-100 is the patented lead drug candidate of
Melt Pharmaceuticals, Inc. and was developed as a means for
providing moderate conscious sedation without an IV or opioids for
patients undergoing cataract surgery and other in-office,
out-patient and hospital-based procedures. The MELT-100 drug
candidate is designed to be administered sublingually, whereby the
medication dissolves under the tongue for absorption into the
bloodstream. If approved, Harrow Health, Inc. is entitled to
receive royalties on the sales of MELT-100.
About Harrow Health
Harrow Health, Inc. (NASDAQ: HROW) owns a
portfolio of healthcare businesses, including the nation’s leading
ophthalmology pharmaceutical compounding business,
ImprimisRx. The company holds large equity positions in Eton
Pharmaceuticals, Surface Pharmaceuticals, Melt Pharmaceuticals,
Mayfield Pharmaceuticals and Radley Pharmaceuticals, all companies
founded as subsidiaries of Harrow Health. The Company also
owns royalty rights in certain 505(b)(2) drug candidates being
developed by Eton, Surface, Melt, Mayfield and Radley. Harrow
intends to create, invest in and grow paradigm shifting health care
businesses that put patients first. For more information
about Harrow Health, please visit the Investor Relations section of
the corporate website by clicking here.
Forward-Looking Statements
This press release contains forward-looking
statements within the meaning of the U.S. Private Securities
Litigation Reform Act of 1995. Any statements in this release that
are not historical facts may be considered such "forward-looking
statements." Forward-looking statements are based on management's
current expectations and are subject to risks and uncertainties
which may cause results to differ materially and adversely from the
statements contained herein. Some of the potential risks and
uncertainties that could cause actual results to differ from those
predicted include our ability to make commercially available our
compounded formulations and technologies in a timely manner or at
all; physician interest in prescribing our formulations; risks
related to our compounding pharmacy operations; our ability to
enter into other strategic alliances, including arrangements with
pharmacies, physicians and healthcare organizations for the
development and distribution of our formulations; our ability to
obtain intellectual property protection for our assets; our ability
to accurately estimate our expenses and cash burn, and raise
additional funds when necessary; risks related to research and
development activities; the projected size of the potential market
for our technologies and formulations; unexpected new data, safety
and technical issues; regulatory and market developments impacting
compounding pharmacies, outsourcing facilities and the
pharmaceutical industry; competition; and market conditions. These
and additional risks and uncertainties are more fully described in
Harrow Health’s filings with the Securities and Exchange
Commission, including its Annual Report on Form 10-K and its
Quarterly Reports on Form 10-Q. Such documents may be read free of
charge on the SEC's web site at www.sec.gov. Undue reliance should
not be placed on forward-looking statements, which speak only as of
the date they are made. Except as required by law, Harrow Health
undertakes no obligation to update any forward-looking statements
to reflect new information, events or circumstances after the date
they are made, or to reflect the occurrence of unanticipated
events.
Investor Contact for Melt:Greg
Madisongmadison@meltpharma.com
Investor Contact for Harrow
Health:Jon Pattonjpatton@harrowinc.com858-704-4587
Source: Harrow Health, Inc. and Melt
Pharmaceuticals, Inc.
Imprimis Pharmaceuticals, Inc. (delisted) (NASDAQ:IMMY)
Historical Stock Chart
Von Mai 2024 bis Jun 2024
Imprimis Pharmaceuticals, Inc. (delisted) (NASDAQ:IMMY)
Historical Stock Chart
Von Jun 2023 bis Jun 2024